tradingkey.logo
tradingkey.logo
Search

Enliven Therapeutics Inc

ELVN
Add to Watchlist
48.800USD
+0.490+1.01%
Close 11-13 16:00(ET)
3.58BMarket Cap
LossP/E TTM

ELVN Financials

See Enliven Therapeutics Inc's financials through an all-in-one data dashboard designed for smart investors. This provides you with financial analysis by organizing complex financial statements into customizable views. Access the latest annual financial report or break down performance quarter-by-quarter using the income statement, balance sheet, and cash flow statement. With real-time financial indicators at your fingertips, monitoring a company's market health over time has never been easier.
Key Financial Ratios
Market Cap
3.58B
Dividend TTM
0.00
P/E TTM
-29.82
EPS TTM
-1.64
Revenue
--
Net Profit
-89.02M
ROE
-26.64%
ROA
-25.74%
Enliven Therapeutics Inc Earnings Date
Latest Release
Nov 5, 2026
EPS / Forecast
-0.36/-0.45
Revenue / Forecast
--/0.00

Financial Statement Highlights

Quarterly
Quarterly+Annual
Quarterly
Annual
FY2026Q3
FY2026Q2
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021Q4
Financial Indicators
EPS
-9.48%-0.36
-0.96%-0.49
34.03%-0.38
-2.51%-0.48
32.36%-0.32
-17.17%-0.49
-5.46%-0.57
1.18%-0.46
5.22%-0.48
-1.66%-0.41
32.00%-0.54
-109.60%-0.47
---0.51
---0.41
---0.80
--4.90
----
----
----
----
Net Profit
-37.50%-27.70M
-28.22%-32.48M
17.23%-23.63M
-27.99%-29.67M
12.99%-20.15M
-26.99%-25.34M
-25.53%-28.54M
-19.67%-23.18M
-11.49%-23.16M
-19.31%-19.95M
-54.43%-22.74M
-160.18%-19.37M
-350.62%-20.77M
-46.05%-16.72M
-0.58%-14.72M
324.77%32.19M
66.23%-4.61M
13.01%-11.45M
-42.72%-14.64M
-24.32%-14.32M
Debt to assets ratio
----
----
----
----
----
----
----
----
----
----
----
--0.00%
--0.00%
--0.00%
--0.00%
--0.00%
----
----
----
----
Operating profit
-43.63%-36.05M
-30.17%-37.21M
12.21%-27.82M
-27.47%-34.28M
7.29%-25.10M
-16.18%-28.58M
-21.96%-31.69M
-18.33%-26.90M
-11.63%-27.07M
-22.20%-24.60M
-58.28%-25.99M
-597.85%-22.73M
-401.93%-24.25M
-74.76%-20.13M
-11.98%-16.42M
77.28%-3.26M
64.63%-4.83M
12.51%-11.52M
-42.62%-14.66M
-24.10%-14.33M
Net Profit
-37.50%-27.70M
-28.22%-32.48M
17.23%-23.63M
-27.99%-29.67M
12.99%-20.15M
-26.99%-25.34M
-25.53%-28.54M
-19.67%-23.18M
-11.49%-23.16M
-19.31%-19.95M
-54.43%-22.74M
-160.18%-19.37M
-350.62%-20.77M
-46.05%-16.72M
-0.58%-14.72M
324.77%32.19M
66.23%-4.61M
13.01%-11.45M
-42.72%-14.64M
-24.32%-14.32M
Current assets
85.37%894.76M
83.07%907.34M
57.36%463.14M
49.27%474.88M
62.52%482.68M
55.79%495.62M
-12.72%294.32M
19.53%318.13M
10.57%297.00M
12.34%318.13M
13.15%337.20M
196.92%266.15M
354.46%268.61M
340.70%283.18M
279.49%298.00M
-3.30%89.64M
-44.24%59.10M
-9.95%64.26M
-2.28%78.53M
2.53%92.70M
Total current liabilities
32.92%19.47M
-6.90%14.16M
-17.79%11.49M
4.10%16.57M
-13.96%14.65M
-31.19%15.21M
-44.18%13.97M
-38.54%15.91M
40.96%17.03M
141.66%22.11M
128.76%25.03M
1314.97%25.89M
564.41%12.08M
177.01%9.15M
51.49%10.94M
-74.62%1.83M
-74.71%1.82M
-52.65%3.30M
31.26%7.22M
15.42%7.21M
Total assets
82.78%897.23M
80.64%910.22M
53.63%464.85M
46.17%476.17M
60.72%490.88M
54.07%503.89M
-11.73%302.57M
19.82%325.76M
11.45%305.43M
13.36%327.04M
13.18%342.78M
195.64%271.87M
363.66%274.04M
346.14%288.50M
271.15%302.87M
-1.80%91.96M
-44.78%59.10M
-10.77%64.67M
-0.10%81.60M
3.09%93.65M
Total liabilities
37.45%20.28M
-2.21%15.07M
-19.53%11.49M
4.10%16.57M
-13.36%14.75M
-30.28%15.41M
-43.05%14.27M
-38.70%15.91M
38.51%17.03M
132.58%22.11M
118.91%25.07M
1318.63%25.96M
576.18%12.29M
187.92%9.51M
24.59%11.45M
-75.97%1.83M
-76.25%1.82M
-55.98%3.30M
50.83%9.19M
18.87%7.62M
Total equity
84.19%876.95M
83.25%895.15M
57.26%453.37M
48.33%459.60M
65.09%476.12M
60.19%488.47M
-9.26%288.30M
26.00%309.85M
10.18%288.40M
9.30%304.93M
9.02%317.71M
172.84%245.91M
356.91%261.75M
354.65%278.99M
302.44%291.42M
4.76%90.13M
-42.35%57.29M
-5.55%61.36M
-4.21%72.41M
1.89%86.03M
Net operating income
5.45%-12.55M
-8.64%-18.53M
20.04%-19.29M
7.93%-15.84M
-8.91%-13.28M
16.53%-17.06M
-3.28%-24.13M
-37.82%-17.20M
23.29%-12.19M
-69.60%-20.43M
-12.08%-23.36M
-563.94%-12.48M
-278.34%-15.89M
2.26%-12.05M
-21.47%-20.84M
84.94%-1.88M
61.46%-4.20M
-18.93%-12.33M
-31.80%-17.16M
-50.99%-12.48M
Net investment
748.84%26.33M
-140.52%-441.57M
2880.10%42.53M
1602.75%12.38M
-127.37%-4.06M
-445.34%-183.59M
107.98%1.43M
-98.12%727.00K
141.71%14.83M
77.78%-33.66M
-57593.55%-17.89M
-7.49%38.69M
-254.00%-35.55M
-2514.24%-151.52M
-100.58%-31.00K
388.59%41.82M
361.37%23.08M
85.24%6.28M
-70.85%5.33M
-168.32%-14.49M
Net financing
748.64%2.39M
112.21%463.42M
4196.15%10.05M
-98.44%623.00K
-132.95%-368.00K
11991.81%218.38M
-99.74%234.00K
44313.33%39.97M
362.82%1.12M
164.04%1.81M
-61.98%90.27M
107.30%90.00K
---425.00K
---2.82M
--237.44M
-12230.00%-1.23M
-100.00%0.00
-100.00%0.00
-100.00%0.00
-101.68%-10.00K

FAQs

What are the current assets of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its current assets were 474.88M, with a year-on-year change of 49.27.

What are the total assets of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its total assets of Enliven Therapeutics Inc were 476.17M, with a year-on-year change of 46.17.

What are the total liabilities of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its total liabilities of Enliven Therapeutics Inc were 16.57M, with a year-on-year change of 4.10.

What is the total equity of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its total equity of Enliven Therapeutics Inc was 459.60M, with a year-on-year change of 48.33.

What is the net operating income of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its net operating income of Enliven Therapeutics Inc was -119.66M, with a year-on-year change of -14.45.

What is the net investment of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its net investment of Enliven Therapeutics Inc was -173.84M, with a year-on-year change of -382.93.

What is the net financing of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its net financing of Enliven Therapeutics Inc was 218.87M, with a year-on-year change of 64.36.

What is the Earnings Per Share (EPS) of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its Earnings Per Share (EPS) was -1.83, with a year-on-year change of 3.24.

What is the net income of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its net income was -103.69M, with a year-on-year change of -16.48.

What is the Return on Equity (ROE) of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its Return on Equity (ROE) was -26.95, with a year-on-year change of 15.87.

What is the Return on Assets (ROA) of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its Return on Assets (ROA) was -25.86, with a year-on-year change of 13.20.

What is the operating profit of Enliven Therapeutics Inc?

According to Enliven Therapeutics Inc's FY2025 earnings report, its operating profit was -119.66M, with a year-on-year change of -14.45.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.